1. Chemical Structures and Properties
- LCZ696 Intermediate II (CAS No.: 1012341-48-8):
- Chemical Name: (R,E)-5-([1,1′-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid
- Molecular Formula: C₂₃H₂₇NO₄
- Molecular Weight: 381.46 g/mol
- Function: Acts as a key intermediate in the synthesis of LCZ696, contributing to the formation of the active pharmaceutical ingredient (API).
- LCZ696 Intermediate N-3 (CAS No.: 1012341-50-2):
- Chemical Name: (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
- Molecular Formula: C₂₃H₂₉NO₄
- Molecular Weight: 383.48 g/mol
- Function: Also serves as an intermediate in the synthesis of LCZ696, playing a distinct role in the chemical pathway leading to the final drug.
2. Structural Differences
- Stereochemistry and Configuration: The two intermediates differ in their stereochemistry and the configuration of certain functional groups. For example:
- LCZ696 Intermediate II has an E-double bond (indicated by “(R,E)”) and a pent-2-enoic acid moiety.
- LCZ696 Intermediate N-3 lacks the double bond and has a pentanoic acid structure, with specific (2R,4S) stereochemistry.
- Functional Groups: The presence or absence of the double bond and the arrangement of substituents (e.g., methyl, tert-butoxycarbonyl) distinguish these intermediates chemically.
3. Synthetic Roles
- LCZ696 Intermediate II: Likely involved in earlier stages of the synthetic route, contributing to the formation of key chiral centers or reactive sites that are essential for the final drug’s structure.
- LCZ696 Intermediate N-3: May serve as a later-stage intermediate, participating in reactions that finalize the drug’s molecular architecture or protect/deprotect functional groups during synthesis.
4. Physical and Chemical Properties
- Molecular Weight: LCZ696 Intermediate N-3 is slightly heavier (383.48 g/mol) compared to LCZ696 Intermediate II (381.46 g/mol) due to differences in molecular structure.
- Reactivity: The presence of the double bond in LCZ696 Intermediate II may influence its reactivity in coupling or cyclization reactions, whereas LCZ696 Intermediate N-3’s structure may favor different reaction pathways.
5. Applications and Uses
- Both intermediates are exclusively used in the pharmaceutical industry for the synthesis of LCZ696, a medication approved for treating heart failure.
- Their specific roles in the synthetic route depend on the chemical transformations required to build the complex structure of sacubitril/valsartan.
6. Safety and Handling
- As chemical intermediates, both compounds require careful handling under controlled conditions to prevent exposure and ensure safety in industrial or laboratory settings.
- Safety data sheets (SDS) for each intermediate would provide detailed information on hazards, protective measures, and emergency procedures.
